Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal cancer.

Enrichetta Corgna1, Maura Betti, Gemma Gatta

  • 1Ospedale Silvestrini, Azienda Ospedaliera di Perugia, Italy. ecorgna@libero.it

Critical Reviews in Oncology/Hematology
|July 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International variation in child healthcare practices and implications for childhood cancer diagnosis: a scoping review and cross-country clinician survey.

European journal of pediatrics·2026
Same author

Neuroblastoma by Stage at Diagnosis and Other Prognostic Factors: The Results of the BENCHISTA Italian Project-A Population-Based Study.

Cancers·2026
Same author

Stage at Diagnosis and International Survival Variation in Childhood Tumors in the BENCHISTA Study.

JAMA network open·2026
Same author

Improving the Connection Between Population-Based and National Clinical Pediatric Cancer Registries-A Pilot Study on Neuroblastoma: The Italian BENCHISTA-Ita Project.

Cancers·2025
Same author

Benchmarking nazionale della sopravvivenza per stadio alla diagnosi dei tumori infantili in Italia (BENCHISTA-ITA): protocollo di studio.

Epidemiologia e prevenzione·2025
Same author

Skin melanoma survival is improving in Europe but regional differences persist: Results of the EUROCARE-6 study.

European journal of cancer (Oxford, England : 1990)·2025

Renal cancer, a common malignancy in European men, often presents late. Antiangiogenic therapies targeting VEGF show promise for advanced kidney cancer, offering new treatment avenues.

Area of Science:

  • Oncology
  • Urology

Background:

  • Renal cancer is the seventh most common male malignancy in Europe, with significant annual new cases.
  • Risk factors include tobacco use, obesity, poor diet, occupational exposures, and family history.
  • The cancer often remains asymptomatic until advanced stages, with classic symptoms presenting in only 9% of cases.

Purpose of the Study:

  • To summarize the epidemiology, clinical presentation, staging, and treatment of renal cancer.
  • To highlight the challenges in chemotherapy and the emerging role of targeted therapies.

Main Methods:

  • Review of epidemiological data and clinical presentation of renal cancer.
  • Discussion of diagnostic techniques, including computed tomography (CT) scans.
  • Analysis of current treatment strategies, including surgery and systemic therapies.

Related Experiment Videos

Main Results:

  • Renal cancer presents with localized, locally advanced, or metastatic disease in 45%, 25%, and 30% of patients, respectively.
  • Survival rates are significantly lower for metastatic renal carcinoma (0-20% five-year survival).
  • Radical nephrectomy is standard; chemotherapy shows limited efficacy due to intrinsic resistance.

Conclusions:

  • Biologic agents, particularly antiangiogenic strategies like VEGF neutralization, are crucial for managing metastatic renal cancer.
  • Early detection and treatment of localized tumors improve survival outcomes.
  • Further research into effective systemic therapies is warranted for advanced renal carcinoma.